This week in therapeutics




Licensing status

Publication and contact information


Breast cancer

Signal transducer and activator of transcription 5 (STAT5)

Human tissue sample and mouse studies suggest inhibiting STAT5 could help reduce the risk of breast cancer associated with late-age pregnancy. Mice that had been pregnant had greater numbers of tumors and levels of Stat5 in precancerous lesions than unmated mice. In precancerous lesion-bearing mice that had been pregnant, a Stat5 inhibitor decreased tumor incidence and increased tumor-free survival compared with vehicle. Tissue from patients with breast cancer who had been pregnant had higher numbers of STAT5+ lesions compared with patients who had never been pregnant. Next steps could include designing specific inhibitors of STAT5 and testing them in preclinical models of pregnancy-associated breast cancer.
The STAT5 inhibitor used in the study, StemMed Ltd.'s C188-9, is in preclinical testing in breast cancer.

SciBX 7(6); doi:10.1038/scibx.2014.163
Published online Feb. 13, 2014

Patented by Baylor College of Medicine; licensed to StemMed

Haricharan, S. et al. eLife;
published online Dec. 31, 2013;
Contact: Yi Li, Baylor College of Medicine, Houston, Texas